Cited evidence brief · updated 31 August 2026

Pill swallowing, oral sprays and what the evidence actually shows.

A cited evidence brief on pill-swallowing difficulty, older-adult dysphagia, vitamin D oral-spray studies and dietary-supplement regulatory boundaries.

Scope: This is an evidence-transparency resource, not a clinical guideline and not proof of Nutrioz-specific bioavailability.
01

Solid dosage forms create a real use barrier

A 2022 narrative review reports that up to 40% of people experience difficulty swallowing solid oral dosage forms. A separate U.S. study found that many adults encounter pills that are hard to swallow; some participants reported abandoning or rejecting treatment because of pill properties.

These findings support designing alternatives to hard-to-swallow tablets and capsules. They do not establish that any particular alternative is clinically superior.

02

Dysphagia prevalence depends on population and assessment

A systematic review and meta-analysis reported substantially different dysphagia prevalence estimates across community-dwelling, hospitalized and nursing-home older adults, and across screening methods. That variation is one reason a product format should not be described as universally safe or suitable for dysphagia.

A non-pill format can remove the need to swallow a tablet or capsule, but people with a swallowing disorder may still need an individualized speech-language pathology or clinical assessment before using any oral product.

03

Vitamin D oral-spray evidence is formulation-specific

Randomized studies have shown that specific vitamin D oral-spray formulations can raise or maintain serum 25-hydroxyvitamin D in specific populations. One healthy-adult trial found no significant difference between the tested capsule and two spray formulations at the studied dose. Other studies used different nanoemulsions, dosing schedules and patient groups.

The correct conclusion is not that every spray absorbs better. Evidence must be linked to the exact formulation, dose, population and outcome. Findings from another company’s product cannot prove Nutrioz-specific bioavailability.

04

FDA registration is not FDA approval

The U.S. Food and Drug Administration does not pre-approve dietary supplements for safety and effectiveness. FDA also states that facility registration or inspection does not mean the agency has approved the facility or its products.

Dietary-supplement companies remain responsible for safety, labeling and applicable current good manufacturing practice requirements.

05

What Nutrioz can claim today

Nutrioz can factually describe a measured 0.06 ml oral-spray format, the current label ingredients and amounts, the absence of a tablet or capsule, and current documented manufacturing and quality facts.

Until product-specific clinical evidence supports more, Nutrioz should not claim universal digestive bypass, direct-to-bloodstream delivery, a fixed absorption multiplier, disease treatment, injection equivalence, or guaranteed suitability for dysphagia.